Unlock instant, AI-driven research and patent intelligence for your innovation.

Anti-il-25 antibodies and use thereof

One-IL-25, IL-25 technology, applied in the direction of antibodies, antibody medical components, applications, etc., can solve the problem of little understanding of the significance of white blood cell anti-tumor immune function

Active Publication Date: 2021-04-09
SUZHOU KANOVA BIOPHARM CO LTD +1
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] During breast cancer development, the presence of increased leukocytes in the tumor stroma parallels disease progression; however, the functional significance of leukocytes in regulating tumor-promoting versus anti-tumor immunity in the breast remains poorly understood

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-il-25 antibodies and use thereof
  • Anti-il-25 antibodies and use thereof
  • Anti-il-25 antibodies and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0121] Example 1. Preparation of Anti-IL-25 Antibody

[0122] IL-25KO mice (16-18g, 6 weeks old, n=3) were immunized by subcutaneous injection of 10 μg human IL-25 protein (NCBI Gene ID: 64806) with complete Freund's adjuvant (Sigma-Aldrich, Cat#F6881) , provided by Professor Chen Dong's laboratory at Tsinghua University), the human IL-25 protein was prepared in-house according to general standard methods for protein expression. Immunization was repeated 5 times at 3-day intervals. 3 days after the last booster, carefully dissect the lymph nodes close to the injection site. Lymphocytes were mixed with Ag8.653 myeloma cells (Sigma-Aldrich , Cat#85011420) fusion and cloned with HAT selection (Sigma cat#: H0262) and HFCS (Hybridoma Fusion and Cloning Supplement, 50X, Roche cat#: 11-363-735-001). The hybridoma supernatants were screened by ELISA to prepare antibodies that can bind to human IL-25. In addition, antagonistic anti-IL-25 mAbs were selected based on cell-based funct...

Embodiment 2

[0150] Example 2. Expression and Purification of Anti-IL-25 Antibodies

[0151] DNA sequences encoding humanized IgG heavy chain (variable domain amino acid sequence of SEQ ID NO: 7, 8 or 9) and light chain (variable amino acid sequence of SEQ ID NO: 10 or 11) were synthesized and synthesized. The pCDNA3.1 vector (commercially available from LifeTechnology) was inserted to construct an expression plasmid for full-length IgG. Expression of the parental antibody was performed in 100 ml of HEK293 cell culture (HEK293 cells are commercially available from ThermoFisher Scientific), and the supernatant was purified with a protein A affinity column (commercially available from GE Healthcare life Science). Purified antibodies were buffer exchanged into PBS using PD-10 desalting columns (commercially available from Thermofisher Scientific). The concentration and purity of the purified protein were determined by OD280 and SDS-PAGE, respectively. Humanized antibodies were expressed in ...

Embodiment 3

[0152] Example 3. SPR analysis of the binding affinity of anti-IL-25 antibody to human IL-25

[0153] An anti-human Fcγ-specific antibody (Jackson Immuno Research, Lot #124448, code 109-008-098) was immobilized on a Biacore T200 sensor chip using the amine coupling method. The four antibodies secreted into the culture medium were injected along with the parental antibody and captured by the anti-human Fc antibody alone by the Fc (capture phase). After equilibration, IL-25 was injected for 300 seconds (association period), followed by running buffer for 1200 seconds (dissociation period). The response of the reference flow cell (flow cell 1 ) was subtracted from those of the humanized antibody flow cell during each cycle. The surface was regenerated prior to injection of another humanized antibody. This process was repeated until all antibodies were analyzed. The off-rates of the humanized antibodies were obtained by locally fitting the experimental data to a 1:1 interaction...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides anti-IL-25 antibodies that are directed against (human) IL-25, nucleic acids that encode such antibodies, compositions, and in particular pharmaceutical compositions that comprise such antibodies; and uses of such antibodies and compositions.

Description

[0001] field of invention [0002] The present invention relates to anti-IL-25 antibodies directed against (human) IL-25; to nucleic acids encoding such antibodies; to compositions (and in particular pharmaceutical compositions) comprising such antibodies; and to such antibodies and combinations use of things. Background technique [0003] IL-25 is a 20 KDa protein, commonly referred to as IL-17E, which is encoded by chromosome 14 and contains 117 amino acids. The IL-17 family of cytokines consists of six members; IL-17A to IL-17F, of which IL-25 (i.e., IL-17E) has a unique structure and function (Iwakura Y et al., Immunity 2011;34:149–162 ; Chang SH, Dong C. Cell Signal 2011; 23:1069–1075.). The receptor for IL-25 (IL-17BR) is highly expressed on primary Th2 cells (Rouvier E et al., J. Immunol., 1993; 150:5445-5456). IL-25 regulates the internal safety of the adaptive immune response that leads to the initiation of allergic disease and plays a role in stimulating lung muco...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/24C12N15/00C12N15/09C12N15/13C12N15/63C12N5/10C12N1/19C12N1/15C12N1/21A61K39/00A61K39/395A61P11/06
CPCA61P11/06C07K16/244C07K2317/24C07K2317/33C07K2317/565C07K2317/76C07K2317/92A61K2039/505
Inventor 郭丽孙甜甜齐晓旭董晨
Owner SUZHOU KANOVA BIOPHARM CO LTD